MX346663B - Lineas de celulas de bajo nivel de fucosa y usos de las mismas. - Google Patents

Lineas de celulas de bajo nivel de fucosa y usos de las mismas.

Info

Publication number
MX346663B
MX346663B MX2013010210A MX2013010210A MX346663B MX 346663 B MX346663 B MX 346663B MX 2013010210 A MX2013010210 A MX 2013010210A MX 2013010210 A MX2013010210 A MX 2013010210A MX 346663 B MX346663 B MX 346663B
Authority
MX
Mexico
Prior art keywords
cells
fucose
population
recombinant proteins
binding agent
Prior art date
Application number
MX2013010210A
Other languages
English (en)
Other versions
MX2013010210A (es
Inventor
Daniel Helman
Meirav Bar-Shimon
Mira Toister-Achituv
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL211583A external-priority patent/IL211583A0/en
Priority claimed from IL217216A external-priority patent/IL217216A0/en
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of MX2013010210A publication Critical patent/MX2013010210A/es
Publication of MX346663B publication Critical patent/MX346663B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01068—Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método de selección de células que tienen cero nivel de fucosa, útiles como células hospederas para la expresión de proteínas recombinantes; el método comprende: (d) introducir mutaciones genéticas en una población de células CHO poniendo en contacto las células con metotrexato (MTX), (e) poner en contacto la población de células CHO que comprenden células mutadas con un agente que se une a la fucosa no tóxico por una cantidad de tiempo que permita la unión del agente que se une a la fucosa a una porción de fucosa sobre la membrana de una célula de la población de células, en donde la cantidad de tiempo no permita la destrucción de las células; y (f) agotar de la población de células que comprenden células mutadas, una subpoblación de células que se unen al agente que se une a la fucosa, seleccionando de esta manera células útiles como células hospederas para la expresión de proteínas recombinantes, las células seleccionadas teniendo cero contenido de fucosa; se describen también células y líneas de células útiles como células hospederas para la expresión de proteínas recombinantes.
MX2013010210A 2011-03-06 2012-03-05 Lineas de celulas de bajo nivel de fucosa y usos de las mismas. MX346663B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL211583A IL211583A0 (en) 2011-03-06 2011-03-06 Low fucose cell lines and uses thereof
IL217216A IL217216A0 (en) 2011-12-27 2011-12-27 Low fucose cell lins and uses thereof
PCT/IL2012/000109 WO2012120500A2 (en) 2011-03-06 2012-03-05 Low fucose cell lines and uses thereof

Publications (2)

Publication Number Publication Date
MX2013010210A MX2013010210A (es) 2013-09-26
MX346663B true MX346663B (es) 2017-03-27

Family

ID=45952581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010210A MX346663B (es) 2011-03-06 2012-03-05 Lineas de celulas de bajo nivel de fucosa y usos de las mismas.

Country Status (14)

Country Link
US (1) US9574003B2 (es)
EP (1) EP2683821B1 (es)
JP (2) JP2014509850A (es)
CN (2) CN103597073B (es)
AU (1) AU2012226398B9 (es)
BR (1) BR112013022832A2 (es)
CA (1) CA2829110C (es)
EA (1) EA032513B1 (es)
ES (1) ES2687771T3 (es)
IL (1) IL228184B (es)
MX (1) MX346663B (es)
SG (1) SG192632A1 (es)
WO (1) WO2012120500A2 (es)
ZA (1) ZA201306336B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
CA2738499A1 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
KR101441437B1 (ko) 2009-06-02 2014-09-25 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US20150322119A1 (en) 2012-12-03 2015-11-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016013109B1 (pt) * 2013-12-09 2021-05-11 Allakos Inc. anticorpo anti-siglec-8, ácido nucleico, vetor, célula hospedeira, composição farmancêutica, seu método de produção e seus usos
EP3122353B1 (en) 2014-03-27 2020-10-28 Vanderbilt University Substituted indole mcl-1 inhibitors
WO2016075662A2 (en) * 2014-11-15 2016-05-19 Zumutor Biologics, Inc. Dna-binding domain, non-fucosylated and partially fucosylated proteins, and methods thereof
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
KR20180068967A (ko) 2015-11-02 2018-06-22 제넨테크, 인크. 단백질의 푸코실화 및 탈푸코실화 형태를 제조하는 방법
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
JP2020518638A (ja) 2017-05-05 2020-06-25 アラコス インコーポレイテッド アレルギー性眼疾患を処置するための方法および組成物
KR102596303B1 (ko) * 2018-08-29 2023-10-30 유나이티드 바이오파마, 인크. 비푸코실화된 항체 및 그의 제조법
AU2018438163A1 (en) * 2018-08-29 2021-04-01 United Biopharma Inc Afucosylated antibodies and manufacture thereof
WO2020090747A1 (ja) 2018-10-29 2020-05-07 株式会社免疫生物研究所 抗ｈｉｖ抗体及びその製造方法
MA55282A (fr) * 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
JP2022526881A (ja) * 2019-03-14 2022-05-27 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
US20220153829A1 (en) * 2019-03-14 2022-05-19 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
CA3177604A1 (en) * 2020-04-17 2021-10-21 Janssen Biotech, Inc. Biosynthetic glycoprotein populations
KR20230087539A (ko) * 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP1060242A4 (en) * 1998-01-23 2003-09-17 Imclone Systems Inc PURIFIED POPULATIONS OF STEM CELLS
HU231090B1 (hu) * 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US6569268B1 (en) * 2000-10-16 2003-05-27 Teck Cominco Metals Ltd. Process and alloy for decorative galvanizing of steel
JP4437015B2 (ja) * 2003-05-21 2010-03-24 タカラバイオ株式会社 肝幹細胞の分離方法
CN101023172A (zh) * 2004-08-05 2007-08-22 协和发酵工业株式会社 糖蛋白质组合物的制造方法
WO2006089232A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against cd30 lacking fucosyl residues
SG187521A1 (en) * 2007-03-07 2013-02-28 Glycofi Inc Production of glycoproteins with modified fucosylation
CN102105490B (zh) * 2008-07-22 2015-08-05 J-制油株式会社 L-岩藻糖α1→6特异性凝集素
JP2012503656A (ja) * 2008-09-26 2012-02-09 エウレカ セラピューティクス，インコーポレイテッド 変異体グリコシル化パターンを有する細胞株およびタンパク質
KR101441437B1 (ko) 2009-06-02 2014-09-25 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
EP2950098A1 (en) * 2009-07-14 2015-12-02 National Institute of Advanced Industrial Science and Technology Glycan markers as measure of disease state of hepatic diseases

Also Published As

Publication number Publication date
WO2012120500A2 (en) 2012-09-13
JP6353023B2 (ja) 2018-07-04
CN109797138A (zh) 2019-05-24
BR112013022832A2 (pt) 2016-11-22
AU2012226398A1 (en) 2013-09-12
EP2683821B1 (en) 2018-07-25
CA2829110A1 (en) 2012-09-13
IL228184B (en) 2018-12-31
JP2014509850A (ja) 2014-04-24
EA032513B1 (ru) 2019-06-28
CN103597073A (zh) 2014-02-19
ZA201306336B (en) 2014-10-29
EP2683821A2 (en) 2014-01-15
SG192632A1 (en) 2013-09-30
AU2012226398B9 (en) 2017-04-13
JP2017079775A (ja) 2017-05-18
WO2012120500A3 (en) 2012-11-15
ES2687771T3 (es) 2018-10-29
AU2012226398B2 (en) 2017-03-23
MX2013010210A (es) 2013-09-26
CN103597073B (zh) 2019-06-07
EA201391282A1 (ru) 2014-04-30
US9574003B2 (en) 2017-02-21
US20140005368A1 (en) 2014-01-02
CA2829110C (en) 2019-01-15

Similar Documents

Publication Publication Date Title
MX346663B (es) Lineas de celulas de bajo nivel de fucosa y usos de las mismas.
NZ586576A (en) Improved mammalian expression vectors and uses thereof
MX357290B (es) Mejoramiento de la actividad de proteínas que requieren centros fe-s.
GEP20217251B (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EA201291024A1 (ru) Композиции эндорибонуклеаз и способы их использования
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
MY162737A (en) 4-1bb binding molecules
SG10201809566SA (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
MX2015017110A (es) Integracion dirigida.
UA115772C2 (uk) Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
WO2010128024A3 (en) Reversibly immortalized cells as well as methods relating hereto
EP4282881A3 (en) Antibodies against csf-1r
NZ702084A (en) System and method for predicting the immunogenicity of a peptide
WO2010120518A3 (en) Sperm cell separation methods and compositions containing sperm cell targeting ligands for use therein
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MX357655B (es) Mediador soluble.
WO2009093242A3 (en) Cell populations for polypeptide analysis and uses of same
MX2013014475A (es) COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR.
UA103624C2 (ru) Антитело, мишенью которого является полипептид baffr
MX353243B (es) Metodo para incrementar la secrecion de proteinas recombinantes.
Bae et al. Development of causal map for greenhouse gas emission in construction
WO2008136253A1 (ja) ウイルスベクターおよびその利用
NZ719884A (en) Methods for monitoring responsiveness to anti-smad7 therapy
NZ730667A (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Legal Events

Date Code Title Description
FG Grant or registration